Literature DB >> 24763614

Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer.

Natalie Hartmann1, Nathalia A Giese1, Thomas Giese2, Isabel Poschke3, Rienk Offringa3, Jens Werner1, Eduard Ryschich4.   

Abstract

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive collagen-rich stroma. T cells that infiltrate pancreatic cancers frequently become trapped in the stroma and do not contact tumor cells. Here, we aimed to analyze how chemokines and extracellular matrix (ECM) collagen interact in mediating T-cell infiltration in PDAC. EXPERIMENTAL
DESIGN: T-cell distribution and ECM structure within tumors were analyzed. Chemokine concentrations in human PDAC were compared with the levels of immune cell infiltration. We assessed the influences of selected chemokines and collagen on directed and random T-cell movement using in vitro migration systems.
RESULTS: PDAC overproduced several T-cell-active chemokines, but their levels were not correlated with intratumoral T-cell infiltration. In the absence of collagen, directed migration of activated T cells was induced by chemokines. Interestingly, collagen itself promoted high migratory activity of T cells, but completely abolished chemokine-guided movement. This effect was not altered by a β1-integrin blocking antibody. Activated T cells actively migrated in low-density collagen matrices, but migration was inhibited in dense collagen. Accordingly, T cells were heterogeneously distributed in the pancreatic cancer stroma, with the majority residing in areas of low-density collagen far from tumor clusters.
CONCLUSION: The excessive desmoplasia in PDAC promotes T-cell migration by contact guidance, which abrogates tumor cell-directed movement. Furthermore, dense collagen networks represent a physical barrier, additionally rearranging T-cell distribution to favor tumor stroma. These mechanisms are mainly responsible for intrastromal T-cell trapping in pancreatic cancer and may hinder the development of T-cell-based immunotherapies. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24763614     DOI: 10.1158/1078-0432.CCR-13-2972

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  66 in total

1.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

Review 2.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

3.  Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.

Authors:  Nikita S Sharma; Vineet K Gupta; Vanessa T Garrido; Roey Hadad; Brittany C Durden; Kousik Kesh; Bhuwan Giri; Anthony Ferrantella; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

4.  Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.

Authors:  Kianna Y Elahi-Gedwillo; Marjorie Carlson; Jon Zettervall; Paolo P Provenzano
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

5.  Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells.

Authors:  Chenxi Tian; Karl R Clauser; Daniel Öhlund; Steffen Rickelt; Ying Huang; Mala Gupta; D R Mani; Steven A Carr; David A Tuveson; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 6.  The fibrotic tumor stroma.

Authors:  Mitsuo Yamauchi; Thomas H Barker; Don L Gibbons; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

Review 7.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

8.  NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.

Authors:  Kirsty Ford; Christopher J Hanley; Massimiliano Mellone; Cedric Szyndralewiez; Freddy Heitz; Philippe Wiesel; Oliver Wood; Maria Machado; Maria-Antoinette Lopez; Anusha-Preethi Ganesan; Chuan Wang; Ankur Chakravarthy; Tim R Fenton; Emma V King; Pandurangan Vijayanand; Christian H Ottensmeier; Aymen Al-Shamkhani; Natalia Savelyeva; Gareth J Thomas
Journal:  Cancer Res       Date:  2020-03-02       Impact factor: 12.701

Review 9.  Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.

Authors:  Elaine Tan; Bassel El-Rayes
Journal:  J Gastrointest Cancer       Date:  2019-03

10.  Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer.

Authors:  J H Park; D C McMillan; J Edwards; P G Horgan; C S D Roxburgh
Journal:  Oncoimmunology       Date:  2016-03-21       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.